睿田生技集結產、學、研三方資源投入，為台灣大學與永齡健康基金會共同合資的第一家產學新創公司，整合了台灣大學的研發實力、台成細胞治療中心在幹細胞領域投入多年的豐富臨床經驗、以及永齡健康基金會長期以來在預防醫學與癌症治療領域投注的龐大資源。 我們從預防醫學的角度出發，由前期的幹細胞、免疫細胞儲存與高端健康管理，方方面面做到個人化的健康管理；藉由前端資訊整合大數據分析，可在未來疾病發生時給予醫療機構最適當處置與疾病管理建議，讓醫療資源得以最大化、最佳化的使用。 Retain Biotech is the first joint venture of National Taiwan University and YongLin Healthcare Foundation, incorporating tripartite resources from industry, academia and research sectors. We integrate the research strength from National Taiwan University, years of extensive clinical experience in the field of stem cell therapy from Tai Chen Cell Therapy Center and vast resources put into the fields of preventive medicine and cancer therapy by YongLin Healthcare Foundation . From the perspective of preventive medicine, Retain Biotech achieves personalized healthcare management with the preservation of stem cells or immune cells at the early stage and high-end healthcare management. By integrating big data analysis, the most appropriate disease management will be provided by our service. When disease occur, we can maximize and optimize the application of medical resources.